Aspen Wealth Strategies LLC Sells 1,418 Shares of Pfizer Inc. (NYSE:PFE)

Aspen Wealth Strategies LLC cut its position in Pfizer Inc. (NYSE:PFE) by 13.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 8,789 shares of the biopharmaceutical company’s stock after selling 1,418 shares during the period. Aspen Wealth Strategies LLC’s holdings in Pfizer were worth $233,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in PFE. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Pfizer in the 4th quarter valued at $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Pfizer by 79.5% in the 4th quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock valued at $295,760,000 after acquiring an additional 4,938,209 shares in the last quarter. Finally, Van ECK Associates Corp raised its holdings in Pfizer by 28.5% in the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after acquiring an additional 4,726,549 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $26.07 on Tuesday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business has a 50-day simple moving average of $26.22 and a two-hundred day simple moving average of $27.10. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $147.72 billion, a PE ratio of 18.49, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 EPS. The business’s revenue was up 24.7% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on PFE. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Wednesday, March 12th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.